Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) Profitability Rank: 9 (As of Jun. 2026) — 13% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0BO Jiangsu Hengrui Pharmaceuticals Co Ltd FRA:0BO
95 GF Score
Price €5.00
GF Value €6.17
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Profitability Rank?

Jiangsu Hengrui Pharmaceuticals Co FRA:0BO 95 Profitability Rank is 9 as of Jun. 2026, which is 13% above its 10-year median of 8.00. GuruFocus rates FRA:0BO with a GF Score™ of 95/100 and a GF Value™ of €6.17 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Jiangsu Hengrui Pharmaceuticals Co has the Profitability Rank of 9. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Jiangsu Hengrui Pharmaceuticals Co's Operating Margin % for the quarter that ended in Jun. 2026 was 22.85%. As of today, Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score is 5.


Jiangsu Hengrui Pharmaceuticals Co Profitability Rank Related Terms


FRA:0BO vs ZTS, UTHR: Profitability Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Profitability Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Profitability Rank falls into.


FRA:0BO
95GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd FRA:0BO
Profitability Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Jiangsu Hengrui Pharmaceuticals Co has the Profitability Rank of 9. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Jiangsu Hengrui Pharmaceuticals Co's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=214.095 / 937.075
=22.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Jiangsu Hengrui Pharmaceuticals Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

Jiangsu Hengrui Pharmaceuticals Co Ltd operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank

Frequently Asked Questions Learn more about Profitability Rank →
What does a Profitability Rank of 9 mean?
Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) has a Profitability Rank of 9 as of Jun. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 13% above median its historical median of 8.00. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Profitability Rank has ranged from 8.00 to 9.00.
Is Jiangsu Hengrui Pharmaceuticals Co's Profitability Rank too high?
Jiangsu Hengrui Pharmaceuticals Co's current Profitability Rank of 9 is 13% above median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 9.00. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Profitability Rank compare to ZTS and UTHR?
Jiangsu Hengrui Pharmaceuticals Co's Profitability Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Profitability Rank has ranged from 8.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Drug Manufacturers company?
A good Profitability Rank depends on the Drug Manufacturers industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. Jiangsu Hengrui Pharmaceuticals Co's current Profitability Rank is 9, which is 13% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.17, compared to a current price of €5.00 — trading 19% below its estimated fair value. The current Profitability Rank is 9, which is 13% above median its 10-year median of 8.00. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO), the current Profitability Rank is 9 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of €5.00 is trading 19% below its estimated GF Value™ of €6.17. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for FRA:0BO:

  • Profitability Rank: 9 (13% above median its 10-year median of 8.00)
  • GF Value™: €6.17 vs. price of €5.00 (19% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the FRA:0BO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
95GF Score

Get the complete analysis for FRA:0BO

Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.00
Price
€6.17
GF Value